Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | CTRC | Q99895 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18733538 | 0.79 | — | — | |
| SCHEMBL23871024 | 0.78 | F2 (0.44) | F2ELANECTSGCTRC | |
| SCHEMBL24658501 | 0.78 | F2 (0.33) | F2ELANECTSGCTRC | |
| SCHEMBL1106709 | 0.77 | — | — | |
| SCHEMBL418457 | 0.77 | F2 (0.36) | F2ELANECTSGCTRCL3MBTL1 | |
| SCHEMBL24658494 | 0.77 | F2 (0.32) | F2ELANECTSGCTRC | |
| SCHEMBL24742080 | 0.75 | — | — | |
| SCHEMBL6362036 | 0.74 | F2 (0.33) | F2ELANECTSGCTRCL3MBTL1 | |
| SCHEMBL22921225 | 0.74 | ENPP2 (0.35) | F2ELANECTSGCTRC | |
| SCHEMBL24658345 | 0.74 | F2 (0.30) | F2ELANECTSGCTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003314-B1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3270909-B1 | FIXED DOSE COMBINATIONS COMPRISING ETC1002 AND ONE OR MORE STATINS FOR TREATING OR REDUCING CARDIOVASCULAR RISK | ESPERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11744816-B2 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | ESPERION THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2023-07-06 | — | — | US | disclosed |
| WO-2022189856-A9 | COMPOUNDS USEFUL FOR TREATING LIVER DISEASES | ABIONYX PHARMA SA (FR) | 2022-10-13 | — | — | WO | disclosed |
| US-20210395175-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210322375-A1 | COMBINATION DRUG FORMULATIONS FOR TREATING PATIENTS WITH CARDIOVASCULAR DISEASE AND ASSOCIATED CONDITIONS | ESPERION THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210322376-A1 | METHODS FOR REDUCING THE RISK OF DIABETES IN PATIENTS BEING TREATED FOR HIGH CHOLESTEROL-RELATED ILLNESSES | GLAS AMERICAS LLC | 2021-10-21 | — | — | US | disclosed |
| US-11116739-B2 | Fixed dose combinations and formulations comprising ETC1002 and one or more statins and methods of treating or reducing cardiovascular disease | GLAS AMERICAS LLC | 2021-09-14 | — | — | US | disclosed |
| US-7335689-B2 | for example, 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid, 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol, 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; treatment of Alzheimer's Disease, metabolic syndrome disorder, cancer, cardiovascular disease, diabetic nephropathy | ESPERION THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1862444-A2 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| US-7304093-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1849760-A1 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070179120-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | ESPERION THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179120-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | ESPERION THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | DASSEUX JEAN-LOUIS H | 2007-06-28 | — | — | US | disclosed |
| US-7192940-B2 | Ether compounds | ESPERION THERAPEUTICS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192940-B2 | Ether compounds | ESPERION THERAPEUTICS, INC. (US) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322376-A1 | METHODS FOR REDUCING THE RISK OF DIABETES IN PATIENTS BEING TREATED FOR HIGH CHOLESTEROL-RELATED ILLNESSES | APOB, HMGCR, ECHS1 | F2 1366/4885ELANE 731/4885CTSG 1873/4885 |
| US-11744816-B2 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | APOB, PCSK9, GOT2 | F2 719/4885ELANE 1034/4885CTSG 1302/4885 |
| US-20210395175-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | NR1H3, CYP27A1, NR1H2 | F2 808/4885ELANE 1498/4885CTSG 2648/4885 |
| US-20070155704-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | F2 495/4885ELANE 938/4885CTSG 2763/4885 |
| US-11116739-B2 | Fixed dose combinations and formulations comprising ETC1002 and one or more statins and methods of treating or reducing cardiovascular disease | APOB, GOT2, HDLBP | F2 832/4885ELANE 1132/4885CTSG 1605/4885 |
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | CYP27A1, NR1H3, PNLIP | F2 914/4885ELANE 827/4885CTSG 2346/4885 |
| US-20070179120-A1 | administering to a patient a hydroxy compound to treat aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, septicemia and syndrome X | PNLIP, NR1H3, CYP27A1 | F2 944/4885ELANE 1135/4885CTSG 2681/4885 |
| US-20210322375-A1 | COMBINATION DRUG FORMULATIONS FOR TREATING PATIENTS WITH CARDIOVASCULAR DISEASE AND ASSOCIATED CONDITIONS | APOB, PCSK9, ECHS1 | F2 714/4885ELANE 358/4885CTSG 1426/4885 |
| US-20070149615-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, GPR119 | F2 495/4885ELANE 938/4885CTSG 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.